Patents by Inventor Lina Q. Setti

Lina Q. Setti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS
    Publication number: 20230278984
    Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
    Type: Application
    Filed: August 3, 2021
    Publication date: September 7, 2023
    Inventors: Lina Q. Setti, Brian Cathers, Zhe Li, Shahul Nilar, James Partridge, Chul Yu, Ming Yu, Manuel Zancanella
  • PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS
    Publication number: 20230159538
    Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
    Type: Application
    Filed: March 31, 2021
    Publication date: May 25, 2023
    Inventors: Ming Yu, Brian Edwin Cathers, Zhe Li, Brian Walter Metcalf, Lina Q. Setti, Chul Yu, Manuel Zancanella
  • PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS
    Publication number: 20230151016
    Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
    Type: Application
    Filed: January 17, 2023
    Publication date: May 18, 2023
    Inventors: Lina Q. Setti, Shahul Nilar, Zhe Li, Ming Yu, Manuel Zancanella
  • Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
    Patent number: 11566030
    Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I: and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: January 31, 2023
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Lina Q. Setti, Shahul Nilar, Zhe Li, Ming Yu, Manuel Zancanella
  • PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS
    Publication number: 20220267337
    Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
    Type: Application
    Filed: February 7, 2022
    Publication date: August 25, 2022
    Inventors: Lina Q. Setti, Shahul Nilar, Zhe Li, Ming Yu, Manuel Zancanella
  • Histone methyltransferase inhibitors
    Patent number: 11254651
    Abstract: The present disclosure provides certain compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease. Also provided are pharmaceutical compositions containing such compounds as well as processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: February 22, 2022
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Ming Yu, Zhe Li, Lina Q. Setti
  • HISTONE METHYLTRANSFERASE INHIBITORS
    Publication number: 20190047981
    Abstract: The present disclosure provides certain compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease. Also provided are pharmaceutical compositions containing such compounds as well as processes and intermediates for preparing such compounds.
    Type: Application
    Filed: February 15, 2017
    Publication date: February 14, 2019
    Inventors: Ming Yu, Zhe Li, Lina Q. Setti
  • Bridged bicyclic kallikrein inhibitors
    Patent number: 10144746
    Abstract: Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: December 4, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Manuel Zancanella, Chul Yu, Lina Q. Setti, Hing Sham, Qing Xu, Calvin W. Yee, Ming Yu
  • BRIDGED BICYCLIC KALLIKREIN INHIBITORS
    Publication number: 20180194780
    Abstract: Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: November 8, 2017
    Publication date: July 12, 2018
    Inventors: Zhe Li, Manuel Zancanella, Chul Yu, Lina Q. Setti, Hing Sham, Qing Xu, Calvin W. Yee, Ming Yu